Results 1 to 10 of about 142,066 (310)

Interstitial lung diseases

Lancet, The, 2022
Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised. Most interstitial lung diseases are characterised by inflammation or fibrosis within the interstitial space, the primary consequence of which is impaired gas ...
Marlies S Wijsenbeek, , Toby M Maher
exaly   +4 more sources

Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases [PDF]

International Journal of Molecular Sciences, 2022
Interstitial lung diseases represent a heterogeneous and wide group of diseases in which factors leading to disease initiation and progression are not fully understood.
Francesco Amati, Marco Mantero, Andrea Gramegna   +2 more
exaly   +4 more sources

Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis

Respiratory Research, 2022
Background Advanced pulmonary sarcoidosis causes significant morbidity and can lead to death. Large trials demonstrated efficacy of antifibrotics in patients with progressive fibrosing interstitial lung diseases (PF-ILD), including a few with sarcoidosis.
M. C. Schimmelpennink, D. B. Meek, A. D. M. Vorselaars, L. C. M. Langezaal, C. H. M. van Moorsel, J. J. van der Vis, M. Veltkamp, J. C. Grutters   +7 more
doaj   +1 more source

Clustering of lung diseases in the family of interstitial lung disease patients

BMC Pulmonary Medicine, 2022
Background The presence of familial interstitial lung disease (ILD) has been found to predict development of progressive pulmonary fibrosis. However, the role of non-ILD lung diseases in ILD patients’ families has not yet been investigated.
Michelle Terwiel, Jan C. Grutters, Coline H. M. van Moorsel   +2 more
doaj   +1 more source

Decreased Survival and Lung Function in Progressive Pulmonary Fibrosis

Medicina, 2023
Background and Objectives: Progressive pulmonary fibrosis (PPF) is a recently described term reserved for patients with fibrotic ILD other than idiopathic pulmonary fibrosis (IPF) with fast clinical deterioration. Here, survival and prognostic biomarkers
Mark G. J. P. Platenburg, Joanne J. van der Vis, Jan C. Grutters, Coline H. M. van Moorsel   +3 more
doaj   +1 more source

No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis

ERJ Open Research, 2023
Background Telomere dysfunction can underly the development of idiopathic pulmonary fibrosis (IPF), and recent work suggests that patients with telomere syndromes might benefit from treatment with androgens, such as danazol.
Thijs W. Hoffman, Coline H.M. van Moorsel, Joanne J. van der Vis, Douwe H. Biesma, Jan C. Grutters   +4 more
doaj   +1 more source

Distinct metabolic features in the plasma of patients with silicosis and dust-exposed workers in China: a case–control study

BMC Pulmonary Medicine, 2021
Background Silicosis is a progressive pneumoconiosis characterized by interstitial fibrosis following exposure to silica dust. The role of metabolic dysregulation in the pathogenesis of silicosis has not been investigated in detail.
Changjiang Xue, Na Wu, Yali Fan, Jing Ma, Qiao Ye   +4 more
doaj   +1 more source

Cluster features in fibrosing interstitial lung disease and associations with prognosis

BMC Pulmonary Medicine, 2023
Background Clustering is helpful in identifying subtypes in complex fibrosing interstitial lung disease (F-ILD) and associating them with prognosis at an early stage of the disease to improve treatment management.
Yuanying Wang, Di Sun, Jingwei Wang, Shiwen Yu, Na Wu, Qiao Ye   +5 more
doaj   +1 more source

Elevated Serum Amyloid a Levels Are not Specific for Sarcoidosis but Associate with a Fibrotic Pulmonary Phenotype

Cells, 2021
Elevated Serum Amyloid A (SAA) levels have been found in several inflammatory diseases, including sarcoidosis. SAA is suggested to be involved in sarcoidosis pathogenesis by involvement in granuloma formation and maintenance.
Els Beijer, Claudia Roodenburg-Benschop, Milou C. Schimmelpennink, Jan C. Grutters, Bob Meek, Marcel Veltkamp   +5 more
doaj   +1 more source

Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE

BMC Pulmonary Medicine, 2023
Background Pulmonary fibrosis (PF) is caused by a heterogeneous group of diseases, with a high inter-individual variability in disease trajectory. Identifying disease progression in patients with PF has impact on clinical management decisions.
Gizal Nakshbandi, Catharina C. Moor, Katerina Antoniou, Vincent Cottin, Anna-Maria Hoffmann-Vold, Edwin A. Koemans, Michael Kreuter, Philip L. Molyneaux, Wim A. Wuyts, Marlies S. Wijsenbeek   +9 more
doaj   +1 more source